Andreas Argyrides
Stock Analyst at Oppenheimer
(4.44)
# 291
Out of 4,944 analysts
104
Total ratings
51.65%
Success rate
20.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALA KALA BIO | Assumes: Outperform | $15 | $7.87 | +90.60% | 1 | Jun 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Assumes: Outperform | $61 | $36.67 | +66.35% | 1 | Jun 2, 2025 | |
| AQST Aquestive Therapeutics | Assumes: Outperform | $15 → $7 | $4.01 | +74.56% | 5 | Jun 2, 2025 | |
| ABEO Abeona Therapeutics | Assumes: Outperform | $19 | $6.56 | +189.63% | 1 | Jun 2, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $60 → $34 | $12.24 | +177.78% | 1 | Jun 2, 2025 | |
| IFRX InflaRx | Maintains: Outperform | $6 → $3 | $0.82 | +267.65% | 2 | May 29, 2025 | |
| LQDA Liquidia | Downgrades: Underperform | $13 | $25.20 | -48.41% | 7 | May 19, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Outperform | $14 → $4 | $0.53 | +657.58% | 5 | May 16, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $155 → $90 | $18.93 | +375.44% | 1 | May 13, 2025 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | $15 → $9 | $2.02 | +345.54% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $47 → $15 | $13.90 | +7.91% | 8 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $191.15 | -5.31% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $12.51 | +179.78% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $3.72 | +598.92% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $55.65 | +86.88% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.45 | +1,023.60% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.97 | +356.85% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $15.82 | +20.10% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $18.05 | +60.66% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $8.92 | +135.56% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $20.40 | +998.04% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $24.96 | +128.41% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.83 | +744.09% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.73 | +168.10% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.54 | +1,753.22% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $58.30 | +20.07% | 6 | Aug 1, 2023 |
KALA BIO
Jun 2, 2025
Assumes: Outperform
Price Target: $15
Current: $7.87
Upside: +90.60%
Harmony Biosciences Holdings
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $36.67
Upside: +66.35%
Aquestive Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $4.01
Upside: +74.56%
Abeona Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $19
Current: $6.56
Upside: +189.63%
Dyne Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $60 → $34
Current: $12.24
Upside: +177.78%
InflaRx
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $0.82
Upside: +267.65%
Liquidia
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $25.20
Upside: -48.41%
Rani Therapeutics Holdings
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.53
Upside: +657.58%
Korro Bio
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $18.93
Upside: +375.44%
ProQR Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.02
Upside: +345.54%
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $13.90
Upside: +7.91%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $191.15
Upside: -5.31%
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $12.51
Upside: +179.78%
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $3.72
Upside: +598.92%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $55.65
Upside: +86.88%
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.45
Upside: +1,023.60%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.97
Upside: +356.85%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $15.82
Upside: +20.10%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $18.05
Upside: +60.66%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $8.92
Upside: +135.56%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $20.40
Upside: +998.04%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $24.96
Upside: +128.41%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.83
Upside: +744.09%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $3.73
Upside: +168.10%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.54
Upside: +1,753.22%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $58.30
Upside: +20.07%